{
  "trial_id": "NCT02279160",
  "trial_group": "hypertension",
  "generated-by-gpt4-omni-zs": {
    "gen-response": "Age, Gender, WHO Group 1 PAH classification, PAH diagnosis confirmation by cardiac catheterization, WHO/NYHA functional class, Stable oral disease-specific PAH therapy, 6MWT distance, Pulmonary function tests (PFTs) results, Ventilation-perfusion (V/Q) lung scan or pulmonary angiogram results, Use of vasodilators, digoxin, spironolactone, or L-Arginine supplementation, Systolic blood pressure, History of left-sided heart disease or clinically significant cardiac disease, Previous use of prostacyclin or prostacyclin analogue, Other severe acute or chronic medical or laboratory abnormalities.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Gender"
        ],
        [
          "PAH Classification",
          "WHO Group 1 PAH classification"
        ],
        [
          "Baseline WHO/NYHA Functional Class",
          "WHO/NYHA functional class"
        ],
        [
          "Baseline 6MWD",
          "6MWT distance"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Ethnicity (NIH/OMB)",
        "Race (NIH/OMB)",
        "Region of Enrollment",
        "Weight",
        "Height",
        "BMI",
        "Duration of PAH (Years)",
        "PAH Treatment",
        "Baseline Pulmonary Vascular Resistance"
      ],
      "remaining_candidate_features": [
        "PAH diagnosis confirmation by cardiac catheterization",
        "Stable oral disease-specific PAH therapy",
        "Pulmonary function tests (PFTs) results",
        "Ventilation-perfusion (V/Q) lung scan or pulmonary angiogram results",
        "Use of vasodilators",
        "digoxin",
        "spironolactone",
        "or L-Arginine supplementation",
        "Systolic blood pressure",
        "History of left-sided heart disease or clinically significant cardiac disease",
        "Previous use of prostacyclin or prostacyclin analogue",
        "Other severe acute or chronic medical or laboratory abnormalities."
      ]
    }
  },
  "generated-by-gpt4-omni-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, WHO/NYHA functional class, Baseline 6-minute walk distance (6MWD), Pulmonary Vascular Resistance (PVR), Type of PAH (IPAH, HPAH, APAH), Stable PAH therapy, Pulmonary function tests (PFTs), Ventilation-perfusion (V/Q) lung scan results, Systolic blood pressure,",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Race (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Baseline WHO/NYHA Functional Class",
          "WHO/NYHA functional class"
        ],
        [
          "Baseline 6MWD",
          "Baseline 6-minute walk distance (6MWD)"
        ],
        [
          "Baseline Pulmonary Vascular Resistance",
          "Pulmonary Vascular Resistance (PVR)"
        ],
        [
          "PAH Classification",
          "Type of PAH (IPAH, HPAH, APAH)"
        ],
        [
          "PAH Treatment",
          "Stable PAH therapy"
        ]
      ],
      "remaining_reference_features": [
        "Ethnicity (NIH/OMB)",
        "Weight",
        "Height",
        "BMI",
        "Duration of PAH (Years)"
      ],
      "remaining_candidate_features": [
        "Pulmonary function tests (PFTs)",
        "Ventilation-perfusion (V/Q) lung scan results",
        "Systolic blood pressure"
      ]
    }
  },
  "generated-by-llama3-70b-in-ts": {
    "gen-response": "Age, Continuous, Sex: Female, Male, Race/Ethnicity, Customized, Region of Enrollment, WHO/NYHA functional class, 6MWT distance, Pulmonary vascular resistance, Systolic blood pressure, Diastolic blood pressure, Body mass index, PAH diagnosis duration, PAH therapy duration.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "Sex: Female"
        ],
        [
          "Male",
          "Male"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "Race/Ethnicity"
        ],
        [
          "Region of Enrollment",
          "Region of Enrollment"
        ],
        [
          "Baseline WHO/NYHA Functional Class",
          "WHO/NYHA functional class"
        ],
        [
          "Baseline 6MWD",
          "6MWT distance"
        ],
        [
          "Baseline Pulmonary Vascular Resistance",
          "Pulmonary vascular resistance"
        ],
        [
          "BMI",
          "Body mass index"
        ],
        [
          "Duration of PAH (Years)",
          "PAH diagnosis duration"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Race (NIH/OMB)",
        "Weight",
        "Height",
        "PAH Treatment",
        "PAH Classification",
        "Baseline Systolic Blood Pressure"
      ],
      "remaining_candidate_features": [
        "Systolic blood pressure",
        "Diastolic blood pressure",
        "PAH therapy duration"
      ]
    }
  },
  "generated-by-llama3-70b-in-zs": {
    "gen-response": "Age, sex, race, ethnicity, weight, height, body mass index (BMI), WHO/NYHA functional class, 6-minute walk distance (6MWD), pulmonary vascular resistance (PVR), systolic blood pressure, diastolic blood pressure, heart rate, medical history (including PAH diagnosis, comorbidities, and concomitant medications), PAH etiology (IPAH, HPAH, drugs and toxins induced, APAH), duration of PAH diagnosis, prior PAH therapy.",
    "evaluated-by-gpt4-omni": {
      "matched_features": [
        [
          "Age",
          "Age"
        ],
        [
          "Sex: Female",
          "sex"
        ],
        [
          "Ethnicity (NIH/OMB)",
          "ethnicity"
        ],
        [
          "Race (NIH/OMB)",
          "race"
        ],
        [
          "Weight",
          "weight"
        ],
        [
          "Height",
          "height"
        ],
        [
          "BMI",
          "body mass index (BMI)"
        ],
        [
          "Duration of PAH (Years)",
          "duration of PAH diagnosis"
        ],
        [
          "PAH Treatment",
          "prior PAH therapy"
        ],
        [
          "PAH Classification",
          "PAH etiology (IPAH, HPAH, drugs and toxins induced, APAH)"
        ],
        [
          "Baseline WHO/NYHA Functional Class",
          "WHO/NYHA functional class"
        ],
        [
          "Baseline Pulmonary Vascular Resistance",
          "pulmonary vascular resistance (PVR)"
        ],
        [
          "Baseline 6MWD",
          "6-minute walk distance (6MWD)"
        ]
      ],
      "remaining_reference_features": [
        "Categorical",
        "Male",
        "Region of Enrollment"
      ],
      "remaining_candidate_features": [
        "systolic blood pressure",
        "diastolic blood pressure",
        "heart rate",
        "medical history (including PAH diagnosis, comorbidities, and concomitant medications)"
      ]
    }
  }
}